NCT04674800View on ClinicalTrials.gov

Extension Study of MYL-1701P-3001 for Safety and Efficacy

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

April 20, 2022

Study Completion Date

April 20, 2022

Conditions
Diabetic Macular Edema
Interventions
BIOLOGICAL

MYL-1701P, a proposed biosimilar to Eylea

Open label and single arm

Trial Locations (15)

110029

Mylan Investigative site, New Delhi

160012

Mylan Investigative Site, Chandigarh

201301

Mylan Investigative Site, Noida

302015

Mylan Investigative site, Jaipur

380015

Mylan Investigative Site, Ahmedabad

380016

Mylan Investigative site, Ahmedabad

400050

Mylan Investigative Site, Mumbai

500034

Mylan Investigative site, Hyderabad

560037

Mylan Investigative Site, Bengaluru

560094

Mylan Investigative Site, Bangalore

627002

Mylan Investigative site, Tirunelveli

751024

Mylan Investigative site, Bhubaneswar

530 040

Mylan Investigative Site, Visakhapatnam

560 010

Mylan Investigative site, Bangalore

625 020

Mylan Investigative site, Madurai

Sponsors
All Listed Sponsors
collaborator

Momenta Pharmaceuticals, Inc.

INDUSTRY

lead

Mylan Pharmaceuticals Inc

INDUSTRY

NCT04674800 - Extension Study of MYL-1701P-3001 for Safety and Efficacy | Biotech Hunter | Biotech Hunter